Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alpha-Phellandrene SCHEMBL159519 | 1.00 | USP2 (0.32) | USP2 | |
| Alpha-Phellandrene SCHEMBL159518 | 1.00 | USP2 (0.32) | USP2 | |
| Alpha-Phellandrene SCHEMBL19816252 | 0.98 | USP2 (0.31) | USP2 | |
| Alpha-Phellandrene SCHEMBL8855951 | 0.90 | — | — | |
| SCHEMBL9070596 | 0.83 | — | — | |
| SCHEMBL13862976 | 0.77 | — | — | |
| (-)-Limonene SCHEMBL6311021 | 0.76 | LMNA (0.63) | — | |
| SCHEMBL13716303 | 0.76 | — | — | |
| SCHEMBL18726658 | 0.76 | — | — | |
| SCHEMBL11981528 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229639-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS Global Biopharma, Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| WO-2023070235-A1 | EXTRACTS OF ESSENTIAL OILS FROM NATIVE FOREST PLANTS, PEUMO, LAUREL, TEPA, CANELO, SCHINUS MOLLE, PARAMELA AND CYPRESS, ANTIMICROBIAL AND ANTITUMOUR COMPOSITION, ANTIMICROBIAL AND ANTITUMOUR HYDROGEL FORMULATION FOR TOPICAL APPLICATION, AND USE THEREOF FOR PREVENTING OR CONTROLLING NOSOCOMIAL DISEASES | UNIVERSIDAD DIEGO PORTALES (CL) | 2023-05-04 | — | — | WO | claimed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| US-20250304517-A1 | STERIOISOMER-SPECIFIC CANNABIS FORMULATIONS AND ANALYSIS | SCIENTIFIC HOLDINGS, LLC (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2025135354-A1 | AGRICULTURAL PESTICIDE COMPOSITION AND USE THEREOF | 농업회사법인 주식회사 쉐어그린 | 2025-06-26 | — | — | WO | disclosed |
| US-12233147-B2 | Method for treating keratin material | HENKEL AG & CO. KGAA (DE) | 2025-02-25 | — | — | US | disclosed |
| CN-118767057-A | Traditional Chinese medicine composition, traditional Chinese medicine preparation, and preparation method and application thereof | 北京青囊惠民医学研究院有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240226034-A1 | Use of Terpenoids and Salicylates as Anesthetics and Analgesics | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-11 | — | — | US | disclosed |
| CN-117486707-A | Synthesis method of diene ligand with chiral bicyclo [2.2.2] skeleton | 南京林业大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-117398424-A | Volatile component of Chinese and Asian artemisia and its pharmaceutical use | 中国中医科学院中药研究所 | 2024-01-16 | — | — | CN | disclosed |
| WO-2022232231-A1 | USE OF TERPENOIDS AND SALICYLATES AS ANESTHETICS, ANALGESICS, AND EUTHANASIA AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20220211601-A1 | METHOD FOR TREATING KERATIN MATERIAL | HENKEL AG & CO. KGAA (DE) | 2022-07-07 | — | — | US | disclosed |
| US-20220204430-A1 | STEREOISOMER-SPECIFIC CANNABIS FORMULATIONS AND ANALYSIS | SCIENTIFIC HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220130493-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-28 | — | — | US | disclosed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | disclosed |
| EP-3946228-A1 | METHOD FOR TREATING KERATIN MATERIAL | Henkel AG & Co. KGaA (DE) | 2022-02-09 | — | — | EP | disclosed |
| CN-113677314-A | Increasing the stability of agents for treating keratin materials | 汉高股份有限及两合公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2020200574-A1 | METHOD FOR TREATING KERATIN MATERIAL | HENKEL AG & CO. KGAA (DE) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233147-B2 | Method for treating keratin material | KRT18, CCNA1, CCNT1 | USP2 1660/4885 |
| US-20220211601-A1 | METHOD FOR TREATING KERATIN MATERIAL | KRT18, CCNA1, CCNT1 | USP2 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.